We use cookies to improve your experience, analyze site usage, and show relevant ads. Go to our Privacy Policy for details.
The call conveyed strong positive progress on the clinical and regulatory front with NDA acceptance and a clear PDUFA date, supported by a broad dataset and active prelaunch preparations. Financially, the company retains a substantial cash balance with runway into 2028 and showed reduced R&D spend following completion of pivotal work. Offsetting risks include a sizeable increase in G&A/prelaunch costs, continued quarterly net losses, competitive timing and pricing pressure from AstraZeneca’s expected earlier launch, and unresolved partnering and labeling/pricing uncertainties. On balance, the company appears well positioned operationally and clinically, but near-term commercial and financial execution risks remain.
On the call Mineralys said the FDA accepted the lorundrostat NDA in Q1 2026 with a PDUFA target date of December 22, 2026, supported by five trials (Launch HTN, Advance HTN, TRANSFORM HTN OLE, TARGET HTN, EXPLORE CKD) demonstrating durable, well‑tolerated blood‑pressure reductions (e.g., ~19 mmHg systolic in Launch) across diverse populations (Black/African‑American representation ~28% to >50%), addressing >20 million U.S. patients with uncontrolled/resistant hypertension and ~8.8M third‑line‑or‑later patient turnover (IQVIA 2024); financially, cash, cash equivalents and investments were $646.1M as of March 31, 2026 (down from $656.6M at 12/31/25) and management said this funding should be sufficient to support planned trials, regulatory activities and operations into 2028; Q1 results included R&D expense $24.4M (Q1’25: $37.9M; driven by a $15.5M reduction in preclinical/clinical costs), G&A $21.0M (Q1’25: $6.6M; including $7.9M higher professional fees and $6.1M higher personnel costs), total other income, net $6.0M (Q1’25: $2.2M) and net loss $39.3M (Q1’25: $42.2M); operational guidance focused on pre‑launch readiness—early market access and payer engagement, expanding sales/marketing and MSL teams—continuing evaluation of partnering opportunities, and plans to publish long‑term OLE/120‑day safety data.
FDA accepted the NDA for lorundrostat for treatment of adult patients with hypertension in combination with other antihypertensives and assigned a PDUFA target date of December 22, 2026 — a major regulatory milestone moving the company closer to a potential U.S. launch.
NDA supported by five trials (Launch HTN, Advance HTN, TRANSFORM HTN OLE, TARGET HTN, EXPLORE CKD) demonstrating clinically meaningful and durable blood pressure reductions, tolerability across diverse populations, and signals relevant to comorbid populations (e.g., proteinuria in CKD).
Company is actively preparing for commercial launch: early market access planning, payer engagement, physician advocacy, publications, scientific meeting participation, expansion of MSL field team, and sales/marketing capability build-out to position lorundrostat for fourth-line (and potentially third-line) use.
Cash, cash equivalents and investments of $646.1M as of March 31, 2026 (down from $656.6M at 12/31/25), with management stating cash is expected to fund planned activities and operations into 2028 (cash decline of approximately -$10.5M, or -1.6%).
R&D expenses for Q1 2026 were $24.4M versus $37.9M in Q1 2025, a decrease of about -35.6%, primarily driven by a reduction in preclinical/clinical costs after completion of the lorundrostat pivotal program.
Net loss narrowed to $39.3M in Q1 2026 from $42.2M in Q1 2025 (an improvement of ~6.9%). Total other income, net, increased to $6.0M from $2.2M (up ~172.7%) reflecting higher interest earned on invested cash balances.
Management cites over 20 million U.S. patients with uncontrolled or resistant hypertension; market research and payer discussions indicate willingness to provide coverage in the fourth-line setting and prescriber receptivity to a novel ASI with strong magnitude/consistency of BP reduction.
Welcome to the Mineralys Therapeutics, Inc. First Quarter 2026 conference call. It is now my pleasure to introduce your host, Dan Ferry of Life Science Advisors. Please go ahead, sir.
Thank you. I would like to welcome everyone joining us today for our first quarter 2026 conference call. This afternoon, after the close of market trading, Mineralys Therapeutics, Inc. issued a press release providing our first quarter 2026 financial results and business updates. A replay of today's call will be available on the Investors section of our website approximately one hour after its completion. After our prepared remarks, we will open up the call for Q&A. Before we begin, I would like to remind everyone that this conference call and webcast will contain forward looking statements about the company. Actual results could differ materially from those stated or implied by these forward looking statements due to risks and uncertainties associated with the company's business.
These forward looking statements are qualified by the cautionary statements contained in today's press release and our SEC filings, including our annual report on Form 10-Ks and subsequent filings. Please note that these forward looking statements reflect our opinions only as of today, May 6, 2026. Except as required by law, we specifically disclaim any obligation to update or revise these forward looking statements in light of new information or future events. I would now like to turn the call over to Jon Congleton, Chief Executive Officer of Mineralys Therapeutics, Inc.
Thank you, Dan. Good afternoon, everyone, and ...